"The guy is not young and from what I have read - Opko is probaly his last project."
He is not young (ie, without experience?) Most do not have the experience he commands.
His last project is going to be, and has always been, his crowning effort.
Apparently you don't get that. In which case, this investment doesn't fit you well (or you don't fit this investment well). I say, in that case, move on. If you do, you will hate me for such advice. But then you asked for it.
And the similarity is there is a fine line between both and insanity.
Who said that?
I said that.
I am Icemandios, and I approve this message. And now back to your regularly scheduled program (of catering to people who have no consequence re the future of OPK).
OPKO's Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe
OPKO Health, Inc. (NYSE:OPK) today announced that the European Committee for Orphan Medicinal Products (COMP) gave a positive opinion recommending the approval of orphan drug designation for OPKO's long-acting version of clotting Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX and congenital Factor VII deficiency. These patients are currently being treated by commercially-available Factor VIIa, with estimated 2013 worldwide sales of $1.7 billion. Factor VIIa-CTP already obtained orphan status in the U.S. earlier this year.
Currently, Factor VIIa therapy is available only as an intravenous (IV) formulation, which requires multiple injections to treat a bleeding episode due to Factor VIIa’s short half-life. In addition, the requirement for multiple weekly injections can be onerous for patients interested in preventative prophylactic treatment of the disease, especially children.
Preclinical data previously presented by OPKO show that OPKO’s long-acting Factor VIIa-CTP has demonstrated the potential for substantial improvement of the quality of life of patients, via both IV and subcutaneous (SC) administration. The combination of a long-acting Factor VIIa coupled with SC administration using a simple injection would potentially change the Factor VIIa market segment, allowing children and adults with hemophilia to be easily self-administered at home on a prophylactic basis.
Dr. Phillip Frost, CEO of OPKO, commented, “We are pleased that the COMP will recommend orphan designation for Factor VIIa-CTP in the EU, as it would allow OPKO 10 years of marketing exclusivity upon commercialization of the drug. We have previously presented data in animal models of hemophilia showing that Factor Vlla-CTP demonstrates superiority of key efficacy and safe
Hey, Max if this stock doesn't fit your plan for investment, then you should find another.
OPK went down today.........and took the whole darn market with it. Go figure.
Maybe it's only a lack of perspective with you. A roach is a giant to an ant. A bird is a giant to a roach. And so on. Everything is relative. Relatively speaking, OPK is doing just fine in the broader context of the market.
Aside from the organized pumps and dumps and shorts and distorts, the only thing that moves stocks these days is news And we will be getting news sooner than later. But if you're having trouble sleeping at night (let alone during the day), then maybe this isn't your cup of tea. Just sayin.
Probably a little too math oriented for the average reader. Consider the fact that modern "cash registers" at most fast food joints do the math (ie, make change known), for them.
I'd guess that "denominator" is likely read as somebody who nominates a democrat. Which makes your assertion inscrutable.
Happy 4th, and a healthy dose of Common Core for all your kids.
Yah, it could happen. But there's only 1 1/2 days left in this week. Half day on Thurs and closed on Fri.
This week, next week, the week after......makes little difference to me.
TESARO Summarizes Rolapitant Data Presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer
MIAMI, June 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that three oral presentations detailing the final results from the rolapitant registration program were delivered today at the MASCC/ISOO International Symposium on Supportive Care in Cancer annual meeting in Miami. Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Dr. Lee S. Schwartzberg, M.D., FACP, Division Chief, Hematology/Oncology and Clinical Instructor at the University of Tennessee Health Sciences Center, presented results of the Phase 3 trial of rolapitant that enrolled 1,369 patients receiving moderately emetogenic chemotherapy (MEC), approximately half of whom were treated with anthracycline-based regimens for breast cancer. This trial successfully achieved the primary endpoint of complete response (CR), defined as no emesis and no use of rescue medication, during the delayed phase following administration of chemotherapy (71.3% for rolapitant-treated patients vs. 61.6% for control, p Dr. Bernardo Rapoport, M.D., Medical Oncologist with Medical Oncology Center of Rosebank in Johannesburg, South Africa, presented the results of two phase 3 trials of rolapitant that together enrolled a total of 1,070 patients receiving cisplatin-based highly emetogenic chemotherapy (HEC). Both Phase 3 studies conducted in patients receiving cisplatin at a dose equal to or greater than 60 mg/m2 met the primary endpoint of complete response in the delayed phase (72.7% vs. 58.4%, p Dr. Allen Poma, M.D., Senior Medical Director at TESARO, presented results of a Phase 1 positron emission tomography (PET) study that assessed rolapitant NK-1 receptor occupancy in the brain, the intended site of action.
OPKO Granted Patent from European Patent Office for Lagova™
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced that the European Patent Office granted OPKO a patent covering the company’s long-acting CTP-enhanced human growth hormone product (Lagova), including composition of matter and associated methods.
The new patent provides OPKO with additional intellectual property protection covering Lagova in Europe, on top of other patents that were previously granted in the U.S. by the U.S. Patent and Trademark Office. OPKO recently announced strong positive results from a Phase 2 study of Lagova in children with growth hormone deficiency. A Phase 3 of Lagova in adults with growth hormone deficiency is ongoing.
About Lagova (hGH-CTP)
In June 2013, OPKO initiated a multi-center worldwide pivotal Phase 3 clinical trial in adults for its proprietary long-acting version of Lagova. Lagova has been awarded orphan drug designation in the U.S. and Europe for both adults and children with growth hormone deficiency.